(NZW x BXSB)F1 mouse. A new animal model of idiopathic thrombocytopenic purpura by unknown
(NZW x BXSB)F1 MOUSE
BriefDefinitive Report
A New Animal Model of Idiopathic Thrombocytopenic Purpura
BY NAOKI OYAIZU,* RYOJI YASUMIZU,*T MUNEO MIYAMA-INABA,*1
SHOSAKU NOMURA,§ HIROTSUGU YOSHIDA,II SHIGEKI MIYAWAKI,II
YOSHIHISA SHIBATA,II SACHIHIKO MITSUOKA,II KOJIRO YASUNAGA,4
SOTOKICHI MORII,* ROBERT A. GOOD,' AND SUSUMU IKEHARA *1
From the *Department of Pathology, the (Department of Immunology, The Liver Research Center,
and the §1st Department of Medicine, Kansai Medical University, Fumizono-cho, Moriguchi City,
Osaka 570, Japan; IIResearch Laboratories, Nippon Shinyaku Co., Ltd ., Sakanotsuji-cho, Oyake,
Yamashina-ku, Kyoto 607, Japan; and (Department of Pediatrics, University of South Florida,
St. Petersburg Florida 33701
There has recently been an increase in data indicating that autoimmune mecha-
nisms are involved in the etiopathogenesis of idiopathic thrombocytopenic purpura
(ITP) (1, 2). Although antibodiesthat react with platelets are found in most patients
with ITP, the pathogenetic nature of the antibodies remains to be clarified. The dis-
covery of an animal model for ITP has therefore been long-awaited. Here we have
found that (NZW x BXSB)Fi (W/B Fi) mice, which develop lupus nephritis with
myocardial infarction (3), show thrombocytopenia with age, and that this is due to
the presence ofboth platelet-associated antibodies(PAA) and circulating antiplatelet
antibodies.
Recently, we have demonstrated that allogeneic bone marrow transplantation
(ABMT) has curative effects on autoimmune diseases in (NZB x NZW)FI, BXSB,
MRL/MP-lpr/lpr (MRL/lpr), and NOD mice (4-6). These results prompted us to
examine whether ABMT can be used to treat ITP. In the present study, we provide
evidence that the transplantation of bone marrow from BALB/c mice to W/B F,
mice does indeed have preventative and curative effects on ITP
Materials and Methods
Mice.
￿
Mice ofthe inbred strain BALB/c nu/nu, BALB/c, C57B/6, C3H/HeN, BXSB, NZW
were raised under specific pathogen-free conditions in our animal facility. W/B F, maleswere
obtained from the Nippon Shinyaku Research Laboratories, Kyoto, Japan.
Staining Procedure andData Analysis.
￿
Platelet-rich plasma was obtained as described previ-
ously (7). The platelets were suspended in 1% paraformaldehyde solution for 5 min. After
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TABLE I
Counts of Platelets and Megakaryocyles in (NZW x BXSB)F, (W/B FI) Mice
* p < 0.001 vs . data in young (1-2.5 mo) W/B F1 mice.
washing twice, the platelets were resuspended in EDTA-PBS to a platelet count of 2 x 10`'/100
pl. To detect the circulating antibodies, aliquots of platelets were incubated with 100 Al of
plasma (1 :4 dilution) for 30 min at room temperature. As a postive control, the platelets of
BALB/c mice were treated with anti-H-2' sera. After washing twice, they were then in-
cubated with a 1 :10 dilution ofFITC-conjugated antisera (goat anti-mouse Ig; Cappel Labora-
tories, West Chester, PA; goat anti-mouse IgG, IgA, IgM; Behring Institute, Marburg, Fed-
eral Republic of Germany) for 30 min at room temperature. After final washing, samples
were then analyzed on a FAGS analyzer (Becton Dickinson & Co., Sunnyvale, CA) by gating
to exclude debrils. The nonstained negative control (autofluorescence) was set at channels
0 to 8. The percentage of positive cells was calculated from the total platelet count above
channel 9 .
Transplantation of Bone Marrow Cells.
￿
3-5-mo-old W/B F, males were exposed to 9.5 Gy
from a 'Co source and then reconstituted by intravenous injection of 1 .4 x 10' bone marrow
cells from BALB/c nu/nu mice, as previously described (4). The mice were killed 5.5 mo after
ABMT.
Platelet andMegakaryocyte Count.
￿
Platelet counts in the peripheral blood were made in heparin
bloodsample on a hemocytometer. For megakaryocyte count, femur and tibiawere obtained
at sacrifice, and sections stained with hematoxylin and eosin. The number of megakaryo-
cytes per square millimeter was counted under a microscope.
Results
Male W/B Ft mice at the age of 1-2 .5 mo showed platelet counts similar to those
of BALB/c, NZW, and BXSB mice (Table I). W/B Ft mice at the age of >4.5 mo,
however, showed a marked reduction in platelet count. In contrast, bone marrow
megakaryocyte counts increased in these mice with age, though they retained their
normal shape.
To elucidate the cause of thrombocytopenia in peripheral blood of W/B Ft mice,
we first examined PAA on the platelets. As shown in Fig. 1, PAA were found in the
platelets of 4.5-mo-old W/B Ft mice with thrombocytopenia (10.5 x 104/pí). BALB/c
platelets treated with anti-H-2' serum were used as a positive control.
The next step was to examine whether circulating antiplatelet antibodies are present
in the plasma of aged W/B F, mice. As shown in Table II, circulating antiplatelet
antibodies were found in the plasma of W/B Ft mice that were >5 mo old.
The characterization of the antiplatelet antibodies revealed that both PAA and
circulating antiplatelet antibodies belong to the IgG and IgM classes, but not IgA
(Table III).
Since we know that ABMT has curative effects on autoimmune diseases (4-6),
W/B Fi mice at the age of3-5 mo were lethally (9.5 Gy) irradiated and then recon-
Mouse Age Sex
Number
examined
Platelet
( x 10-4/Itl)
Mean
Megakaryocytc
(/mmz)
± SD
BALB/c 2-4 mo o' and 9 15 54.0 ± 10.8 1.32 .5 ± 19.1
NZW 4 mo 9 1 46.5 128
BXSB 8 Mo o' 14 57 .9 ± 12 .0 127.2 ± 11 .1
W/B F, 1-2 .5 mo o' 19 52.5 t 10.7 118 .0 ± 12.6
W/B F, 4.5-7 mo a 19 15.0 t 5.9* 150 .8 ± 10.0*m
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FIGURE 1. Platelet-associated
antibodies in W/B Fi mice. Ali-
quots of the platelets (2 x 106)
were labeled with FITC-anti-
mouse Ig and analyzed on a
FAGS analyzer. As a positive
control, BALB/c platelets
treated with anti-H-2a antisera
were used. Platelet counts (Plt.
count: x 10 - s/ml) for each
mouse are shown.
stituted with bone marrow cells from BALB/c nu/nu mice. The mice were killed 5 .5
mo after ABMT W/B F1 mice reconstituted with BALB/c nu/nu bone marrow cells
showed normal platelet counts even at the age of 10.5 mo, and the levels ofantiplatelet
antibodies were reduced to those of BALB/c mice (Table IV).
Discussion
In the present study we have demonstrated that W/B F1 mice develop throm-
bocytopenia with age, and have found the presence of both PAA and circulating
antiplatelet antibodies in such mice.
Several mechanisms that would explain the cause of thrombocytopenia in patients
with ITP have been proposed. One is the presence of antiplatelet antibodies, which
results in platelet destruction by complement-mediated lysis (8) or sequestration by
the reticuloendothelial system (1). It has been reported that the antibodiesin humans
belong mainly to the IgG class (9). In W/B F1 mice, we have found the presence
of IgG and IgM (but not IgA) antibodies both in the plasma and on the platelets
(Table III). Since W/B F1 mice show high levels of circulating immune complexes2020
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TABLE II
Circulating Antiplatelet Antibodies in Old (NZW x BXSB)FI (W/B Fl) Mice
1st antibody
￿
2nd antibody
￿
Percent positive
(plasma from)
￿
Age
￿
(anti-1g)*
￿
(Mean ± SD)
mo
Platelets were obtained from 2-mo-old BALB/c mice.
'" FITC-labeled goat anti-mouse Ig.
" p < 0 .001 vs. data in young (1-2.0 mo) W/B Ft mice.
(CICs) from the age of 2.5 mo (3), it is conceivable that CICs are involved in the
development of thrombocytopenia, CICs beingfoundto affect plateletsby activating
complement or platelet-aggregating factor (1, 2) . However, murine platelets have
TABLE III
Characterization of Antiplatelet Antibodies in Old (NZW x BXSB) Ft (WIB F,) Mice
Platelets used in circulating antibody assay were obtained from 4-wk-old BALB/c mice.
' FITC-labeled goat anti-mouse Ig.
1 Platelet counts were 5.5 x 104/pl .
4 Platelet counts were 13.0 x 104/ul.
II FITC-labeled goat anti-mouse IgG .
Anti-H-2d
BALB/c 1 .5 to 2.0
+
+
+
14.0 _+ 3 .1
54.9 + 1 .8
26.0 + 0 .3
(W/B)Fl 1 .0 + 17 .8
1 .5 + 16 .5
1 .5 + 21 .7
(20 .1 ± 3.5)
1 .5 + 24 .9
2 .0 + 16 .8
2 .0 + 22 .9
(W/B)Fl 5 .0 + 45.3
5 .5 + 49.2
7 .0 + 57.6 (49 .9 ± 4.8)"
7 .0 + 50.7
8 .5 + 46.8
Platelet-associated antibodies Circulating antibodies
Source of
platelet
1st
antibody
2nd
antibody
Percent
positive
1st antibody
(plasma from)
2nd
antibody
Percent
positive
BALB/c - - 2.1 0 .03
Anti-Ig 9 .9 ± 3 .7
BALB/c Anti-H-2d Anti-Ig' 48.9 ± 2.5 Anti-H-2d Anti-Ig 50 .5 ± 0 .2
BALB/c - Anti-Ig 10.7 ± 0.7 BALB/c Anti-Ig 27 .5 ± 8.3
BXSB - Anti-Ig 23.6 ± 1 .2 C57BL/6 Anti-Ig 22 .7 ± 2 .0
BXSB Anti-Ig 24 .8 ± 3 .5
W/B Fi - Anti-Ig 23.1 f 4.2 W/B Fi Anti-Ig 12 .9 ± 1 .3
(1 .0 mo) (1 .0 mo)
W/B Fit - Anti-Ig 44.8 ± 0.8 W/B Ft4 Anti-Ig 52 .8 ± 4.3
(4.5 mo) - IgGll 41 .7 (7 .0 mo) IgG 33 .7 ± 3 .0
- IgA 18.8 IgA 20 .9 + 2 .3
- IgM 30.5 IgM 35 .9 + 0 .4OYAIZU ET AL. BRIEF DEFINITIVE REPORT
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TABLE IV
Effects of Bone Marrow Transplantation on Platelet Counts and Circulating AntiPlatelet
Antibodies in Old (NZW x BXSB)F, (W/B F,) Mice
Platelets were obtained from 2-mo-old BALB/c mice.
FITC-labeled goat anti-mouse Ig.
1 The W/B Ft mice at the age of 3-5 mo were exposed to 9 .5 Gy from a "'Co source and then reconstituted
with 1 .4 x 107 bone marrow cells of BALB/c nu/nu mice. The mice were killed 5.5 mo after bone marrow
transplantation.
9 p < 0 .01 vs. data in old (5-8.5 mo) W/B F I mice without ABMT.
II p < 0 .02 vs. data in old (5-8.5 mo) W/B F t mice without ABMT.
no Fc receptors (2), and the sera from BXSB (Table III) and MRL/lpr (data not
shown) mice, which show high CIC levels, did not bind to the platelets of BALB/c
mice. It is therefore unlikely that antibodies bound to platelets and circulating an-
tiplatelet antibodies exist as a form of CIC.
Hang et al. (10) investigated the etiopathogenesis ofautoimmune diseases in these
W/B F1 mice by reciprocal transfer experiments of spleen cells between males that
exhibit early-onset autoimmune disease and females with late-onset autoimmune
diseases; the transfer of male lymphoid cells to female mice caused the development
of accelerated lupus nephritis, hypertension, and myocardial infarction, whereas the
transfer of female lymphoid cells to male mice delayed the onset. We have recently
demonstrated that the transplantation of bone marrow cells from normal mice to
autoimmune-prone mice has curative effects on autoimmune diseases, such as lupus
nephritis, lupoid hepatitis, rheumatoid arthritis, and type I diabetes mellitus (4-6).
In the present study, W/B F1 mice after ABMT showed normal platelet counts and
no evidence of the presence of circulating antiplatelet antibodies even at the age of
10.5 mo (Table IV). These results provide additional evidence that autoimmune mech-
anisms are involved in the development of thrombocytopenia in W/B F1 mice, al-
though the exact mechanism by which it develops remains to be clarified .
We thus think that W/B 1 mice serve as a useful animal model of ITP not only
for elucidating the mechanism of the development of antiplatelet antibodies, but
also for characterizing autoantibodies to platelets.
1st antibody
(plasma from) Age
mo
Platelet count
(Mean ± SD)
x 10 -{/ul
2nd
antibody
(Anti-1g)*
Percent
positive
(Mean ± SD)
- - 0.1
- + 19.2 + 7 .6
Anti-H-2`1 + 54.3 + 3.9
C3H/HeN 1 .5 35.6 + 33.9
C57BL/6 3 .5 49.6 + 30.6
BALB/c 1 .5 44.8 + 35.3
W/B F1 1 .5 42.7 ± 12 .8 + 27.5 ± 8.8
W/B Ft 5 .0 to 8.5 15.5 ± 1 .6 + 54.3 ± 9,5
(BALB/c - W/B Fill 8.5 33 .2 + 35 .6
9 .5 26.0 + 43 .6
9.5 28 .8 (36.2 ± 10.0)9 + 44.1 (39.6 ± 4.3)11
10 .5 50 .0 + 39 .9
10 .5 43 .2 + 34.82022
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Summary
A decrease in thrombocyte count was observed in (NZW x BXSB)Fi (W/B FI)
mice at the age of >5 mo, whereas megakaryocyte counts were found to increase
in such mice. FACS analyses revealed the presence of both platelet-associated anti-
bodies (PAA) and circulating antiplatelet antibodies. There is a correlation between
the presence of these antibodies and the degree of thrombocytopenia. The trans-
plantation of normal bone marrow cells from BALB/c nu/nu mice to W/B Fi mice
was found to have preventative and curative effects on thrombocytopenia; the mice
showed normal platelet counts and no evidence ofcirculating antiplatelet antibodies.
These results indicate that thrombocytopenia in W/B Fi mice is due to the pres-
ence of antibodies to platelets. We therefore think that W/B F, mice serve as a useful
animal model of idiopathic thrombocytopenic purpura (ITP) not only for elucidating
the mechanism of the development of antiplatelet antibodies, but also for charac-
terizing autoantibodies to platelets.
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